<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter" xml:lang="EN">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Clinics</journal-id>
      <journal-title>Clinics (Sao Paulo, Brazil)</journal-title>
      <issn pub-type="ppub">1807-5932</issn>
      <issn pub-type="epub">1980-5322</issn>
      <publisher>
        <publisher-name>Hospital das Cl&#xED;nicas da Faculdade de Medicina da Universidade de S&#xE3;o Paulo</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">18438586</article-id>
      <article-id pub-id-type="pmc">2664202</article-id>
      <article-id pub-id-type="publisher-id">cln63_2p0281</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letter to the Editor</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Bisphosphonates and Osteonecrosis of the Jaw: A Case Report</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Reiriz</surname>
            <given-names>Andr&#xE9; Borba</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>de Moraes De Zorzi</surname>
            <given-names>Patr&#xED;cia</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lovat</surname>
            <given-names>Cristian Patrik</given-names>
          </name>
        </contrib>
        <aff id="af1-cln63_2p0281">Universidade de Caxias do Sul - Caxias do Sul/RS - Brazil.
<email>lovat@brturbo.com.br</email></aff>
      </contrib-group>
      <pub-date pub-type="ppub">
        <month>4</month>
        <year>2008</year>
      </pub-date>
      <volume>63</volume>
      <issue>2</issue>
      <fpage>281</fpage>
      <lpage>284</lpage>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2008 Hospital das Cl&#xED;nicas da FMUSP</copyright-statement>
        <copyright-year>2008</copyright-year>
      </permissions>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>The incidence of bone metastases is high among patients with advanced cancer. Bone metastases occur in about 80% of men with advanced prostate cancer,<xref ref-type="bibr" rid="b1-cln63_2p0281">1</xref> 75% of patients with metastatic breast cancer<xref ref-type="bibr" rid="b2-cln63_2p0281">2</xref> and 30% to 60% of patients with advanced metastatic lung cancer,<xref ref-type="bibr" rid="b3-cln63_2p0281">3</xref> and are present in 35% of patients with renal cell carcinoma at the time of diagnosis<xref ref-type="bibr" rid="b4-cln63_2p0281">4</xref>.</p>
      <p>Bone metastases cause considerable skeletal morbidity with severe bone pain in some cases, pathologic fractures, spinal cord compression and hypercalcemia. In addition, patients frequently need radiotherapy or surgery to treat bone pain or to prevent pathological fractures.<xref ref-type="bibr" rid="b3-cln63_2p0281">3</xref>,<xref ref-type="bibr" rid="b5-cln63_2p0281">5</xref> Because of this, complications from bone metastases heavily impact the quality of life of patients with cancer. Therefore, the prevention or delay of these complications would be of significant benefit to patients with advanced cancer.<xref ref-type="bibr" rid="b6-cln63_2p0281">6</xref></p>
      <p>The bisphosphonates represent a major advance in helping patients with bone metastases.<xref ref-type="bibr" rid="b7-cln63_2p0281">7</xref> They have been largely used in the treatment of this condition, since they inhibit osteoclastic activity, proliferation of tumor cells and angiogenesis. Bisphosphonates are also used in the treatment of other bone diseases, such as osteoporosis, Paget&#x2019;s disease and malignancy-related hypercalcemia.<xref ref-type="bibr" rid="b8-cln63_2p0281">8</xref>&#x2013;<xref ref-type="bibr" rid="b10-cln63_2p0281">10</xref></p>
      <p>In 1995, intravenous pamidronate was approved for treating patients with multiple myeloma or metastatic breast cancer based on study findings that pamidronate reduces the risk of skeletal complications. In 2002, intravenous zoledronic acid was approved for the treatment and prevention of skeletal complications in patients with multiple myeloma or with bone metastases from any solid tumor type.<xref ref-type="bibr" rid="b11-cln63_2p0281">11</xref>,<xref ref-type="bibr" rid="b12-cln63_2p0281">12</xref> This was the first bisphosphonate with proven efficacy in the treatment of bone metastases from solid tumors, in addition to breast carcinoma.<xref ref-type="bibr" rid="b6-cln63_2p0281">6</xref> Currently, therapy with bisphosphonates is considered standard in the prevention of skeletal complications in patients with bone metastases.<xref ref-type="bibr" rid="b13-cln63_2p0281">13</xref></p>
      <p>Although serious side-effects have been reported, including acute renal failure after intravenous administration and gastrointestinal toxicities such as esophagitis when used orally, these drugs are generally well tolerated<xref ref-type="bibr" rid="b14-cln63_2p0281">14</xref>. Recently, however, a new complication associated with the use of bisphosphonates has been described: osteonecrosis of the jaw. This condition was initially associated with the use of zoledronic acid, but occurrences after pamidronate use have also been reported.<xref ref-type="bibr" rid="b15-cln63_2p0281">15</xref>, <xref ref-type="bibr" rid="b16-cln63_2p0281">16</xref></p>
    </sec>
    <sec sec-type="cases">
      <title>CASE REPORT</title>
      <p>A 57-year-old male patient sought medical help for progressive lumbar pain. Tomographic studies revealed lytic lesions in L1, L2 and L3, and a hypodense lobulated mass in the left kidney. The patient underwent radiotherapy on the lumbar column, followed by a left nephrectomy (renal clearance after this procedure was 80 mL/min) and treatment with 5 MU/m&#xB2; interferon, three times a week, and 4 mg of intravenous zoledronic acid administered as a 15-minute infusion every 4 weeks. After one year of therapy with no evidence of active disease, the patient required invasive dental treatment due to intense pain in his left molar tooth. Fifteen days after this procedure, he developed an ulcerated lesion in his lower jaw with local purulent secretion (<xref ref-type="fig" rid="f1-cln63_2p0281">Figure 1</xref>). In a radiological evaluation, osteonecrosis with bone rarefaction in the regional jaw was discovered (<xref ref-type="fig" rid="f2-cln63_2p0281">Figure 2</xref>).</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>Bisphosphonates are analogous to synthetic pyrophosphate, a natural regulator of bone metabolism that is abundant in the bone matrix.<xref ref-type="bibr" rid="b17-cln63_2p0281">17</xref> These compounds inhibit the differentiation of osteoclastic precursors, lead to osteoclast apoptosis and stimulate the release of osteoclastic inhibitory factor from osteoblasts.<xref ref-type="bibr" rid="b18-cln63_2p0281">18</xref> Numerous clinical studies have shown that bisphosphonates can reduce the incidence of pathological fractures, bone pain, episodes of hypercalcemia and the need for radiotherapy and surgery in patients with osteolytic bone metastases.<xref ref-type="bibr" rid="b19-cln63_2p0281">19</xref>&#x2013;<xref ref-type="bibr" rid="b21-cln63_2p0281">21</xref></p>
      <p>In addition to adverse effects previously associated with the use of bisphosphonates, a new complication has recently been described: avascular osteonecrosis of the jaw.<xref ref-type="bibr" rid="b15-cln63_2p0281">15</xref>,<xref ref-type="bibr" rid="b16-cln63_2p0281">16</xref>,<xref ref-type="bibr" rid="b22-cln63_2p0281">22</xref>&#x2013;<xref ref-type="bibr" rid="b24-cln63_2p0281">24</xref> The incidence of this complication is around 0.03% to 6.2%. This variation mainly depends on the type of analysis.<xref ref-type="bibr" rid="b16-cln63_2p0281">16</xref>,<xref ref-type="bibr" rid="b22-cln63_2p0281">22</xref>,<xref ref-type="bibr" rid="b25-cln63_2p0281">25</xref> Osteonecrosis has been associated with a wide range of conditions, including corticosteroid usage, alcoholism, infections, hyperbaric events, storage disorders, marrow infiltrating diseases, coagulation defects and some autoimmune diseases. However, a large number of idiopathic cases of osteonecrosis have been described without an obvious etiologic factor.<xref ref-type="bibr" rid="b26-cln63_2p0281">26</xref></p>
      <p>The osteoclastic function is part of the cycle of bone turnover. If osteoclastic function is too severely impaired, dead and dying osteocytes are not replaced, and the capillary network in the bone is not maintained, resulting in avascular bone necrosis.<xref ref-type="bibr" rid="b27-cln63_2p0281">27</xref></p>
      <p>Zoledronic acid was the most powerful bisphosphonate investigated in pre-clinical tests of bone resorption.<xref ref-type="bibr" rid="b7-cln63_2p0281">7</xref> However, extended treatments with bisphosphonates increase the risk of osteonecrosis, which is greater with the use of zoledronic acid than with the use of pamidronate in treatments exceeding 36 months.<xref ref-type="bibr" rid="b28-cln63_2p0281">28</xref>,<xref ref-type="bibr" rid="b29-cln63_2p0281">29</xref></p>
      <p>Reports have shown that the majority of patients (69%) had teeth pulled before the development of osteonecrosis. This seems to confirm the importance of this type of trauma in causing the complication,<xref ref-type="bibr" rid="b30-cln63_2p0281">30</xref> and can be explained by the fact that when local defenses are overwhelmed by infection, trauma or surgery, diverse microorganisms may invade the bone marrow. Additionally, the inhibition of angiogenesis can aggravate this process by compromising the vascular supply through tissue cicatrisation.<xref ref-type="bibr" rid="b31-cln63_2p0281">31</xref></p>
      <p>A study that included 225 patients showed that the most common symptom of osteonecrosis is pain (94), followed by purulent secretion (10), oroanthral fistula (7), swelling (3) and fever (1). Data was available for only 115 (51.1%) of these patients. In 14 other patients (12.2%), osteonecrosis was asymptomatic and was discovered through routine tests.<xref ref-type="bibr" rid="b30-cln63_2p0281">30</xref></p>
      <p>Therefore, to avoid osteonecrosis of the jaw, it is recommended that patients who are about to start bisphosphonate therapy have a complete dental exam in order to identify possible existing infections, compromised teeth and dentures that do not fit properly. If therapy with bisphosphonates can be delayed, preventive surgery to eliminate possible infections must be performed. In addition, any jaw or elective maxillary procedure requiring healing should be avoided. Proper dental health during treatment is crucial, and all patients should be informed of the importance of good oral hygiene. In addition, a regular visual inspection by an oncologist and a routine evaluation by a dentist are important.<xref ref-type="bibr" rid="b30-cln63_2p0281">30</xref></p>
      <p>If osteonecrosis develops, non-surgical access can achieve benefits through antibiotic therapy. Interruption of bisphosphonate therapy can be considered in severe cases if the benefits outweigh the risks of skeletal events, although no improvements have been observed in cases published so far.<xref ref-type="bibr" rid="b31-cln63_2p0281">31</xref> Similarly, therapy with hyperbaric oxygen did not prove to be effective.<xref ref-type="bibr" rid="b30-cln63_2p0281">30</xref></p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="b1-cln63_2p0281">
        <label>1</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carlin</surname>
              <given-names>BI</given-names>
            </name>
            <name>
              <surname>Andriole</surname>
              <given-names>GL</given-names>
            </name>
          </person-group>
          <article-title>The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma</article-title>
          <source>Cancer</source>
          <year>2000</year>
          <volume>88</volume>
          <issue>12 Suppl</issue>
          <fpage>2989</fpage>
          <lpage>94</lpage>
          <pub-id pub-id-type="pmid">10898342</pub-id>
        </citation>
      </ref>
      <ref id="b2-cln63_2p0281">
        <label>2</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Harvey</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Cream</surname>
              <given-names>LR</given-names>
            </name>
          </person-group>
          <article-title>Biology of bone metastases: causes and consequences</article-title>
          <source>Clin Breast Cancer</source>
          <year>2007</year>
          <volume>7</volume>
          <issue>Suppl 1</issue>
          <fpage>S7</fpage>
          <lpage>13</lpage>
          <pub-id pub-id-type="pmid">17683652</pub-id>
        </citation>
      </ref>
      <ref id="b3-cln63_2p0281">
        <label>3</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Coleman</surname>
              <given-names>RE</given-names>
            </name>
          </person-group>
          <article-title>Skeletal complications of malignancy</article-title>
          <source>Cancer</source>
          <year>1997</year>
          <volume>80</volume>
          <issue>8 Suppl</issue>
          <fpage>1588</fpage>
          <lpage>94</lpage>
          <pub-id pub-id-type="pmid">9362426</pub-id>
        </citation>
      </ref>
      <ref id="b4-cln63_2p0281">
        <label>4</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zekri</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ahmed</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Coleman</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Hancock</surname>
              <given-names>BW</given-names>
            </name>
          </person-group>
          <article-title>The skeletal metastatic complications of renal cell carcinoma</article-title>
          <source>Int J Oncol</source>
          <year>2001</year>
          <volume>19</volume>
          <fpage>379</fpage>
          <lpage>82</lpage>
          <pub-id pub-id-type="pmid">11445855</pub-id>
        </citation>
      </ref>
      <ref id="b5-cln63_2p0281">
        <label>5</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Coleman</surname>
              <given-names>RE</given-names>
            </name>
          </person-group>
          <article-title>Metastatic bone disease: clinical features, pathophysiology and treatment strategies</article-title>
          <source>Cancer Treat Rev</source>
          <year>2001</year>
          <volume>27</volume>
          <fpage>165</fpage>
          <lpage>76</lpage>
          <pub-id pub-id-type="pmid">11417967</pub-id>
        </citation>
      </ref>
      <ref id="b6-cln63_2p0281">
        <label>6</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lacerna</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Hohneker</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumors</article-title>
          <source>Semin Oncol</source>
          <year>2003</year>
          <volume>30</volume>
          <issue>5 Suppl 16</issue>
          <fpage>150</fpage>
          <lpage>60</lpage>
          <pub-id pub-id-type="pmid">14613036</pub-id>
        </citation>
      </ref>
      <ref id="b7-cln63_2p0281">
        <label>7</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Michaelson</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
          <article-title>Bisphosphonates for treatment and prevention of bone metastases</article-title>
          <source>J Clin Oncol</source>
          <year>2005</year>
          <volume>23</volume>
          <fpage>8219</fpage>
          <lpage>24</lpage>
          <pub-id pub-id-type="pmid">16278476</pub-id>
        </citation>
      </ref>
      <ref id="b8-cln63_2p0281">
        <label>8</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>MV</given-names>
            </name>
            <name>
              <surname>Fong</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Singer</surname>
              <given-names>FR</given-names>
            </name>
            <name>
              <surname>Guenette</surname>
              <given-names>RS</given-names>
            </name>
          </person-group>
          <article-title>Bisphosphonate treatment inhibits the growth of prostate cancer cells</article-title>
          <source>Cancer Res</source>
          <year>2001</year>
          <volume>61</volume>
          <fpage>2602</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">11289137</pub-id>
        </citation>
      </ref>
      <ref id="b9-cln63_2p0281">
        <label>9</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Senaratne</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Pirianov</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Mansi</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Arnett</surname>
              <given-names>TR</given-names>
            </name>
            <name>
              <surname>Colston</surname>
              <given-names>KW</given-names>
            </name>
          </person-group>
          <article-title>Bisphosphonates induce apoptosis in human breast cancer cell lines</article-title>
          <source>Br J Cancer</source>
          <year>2000</year>
          <volume>82</volume>
          <fpage>1459</fpage>
          <lpage>68</lpage>
          <pub-id pub-id-type="pmid">10780527</pub-id>
        </citation>
      </ref>
      <ref id="b10-cln63_2p0281">
        <label>10</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wood</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bonjean</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ruetz</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bellahcene</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Devy</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Foidart</surname>
              <given-names>JM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid</article-title>
          <source>J Pharmacol Exp Ther</source>
          <year>2002</year>
          <volume>302</volume>
          <fpage>1055</fpage>
          <lpage>61</lpage>
          <pub-id pub-id-type="pmid">12183663</pub-id>
        </citation>
      </ref>
      <ref id="b11-cln63_2p0281">
        <label>11</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rosen</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Gordon</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kaminski</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Howell</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Belch</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mackey</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial</article-title>
          <source>Cancer J</source>
          <year>2001</year>
          <volume>7</volume>
          <fpage>377</fpage>
          <lpage>87</lpage>
          <pub-id pub-id-type="pmid">11693896</pub-id>
        </citation>
      </ref>
      <ref id="b12-cln63_2p0281">
        <label>12</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rosen</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Gordon</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Tchekmedyian</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Yanagihara</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hirsh</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Krzakowski</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group</article-title>
          <source>J Clin Oncol</source>
          <year>2003</year>
          <volume>21</volume>
          <fpage>3150</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">12915606</pub-id>
        </citation>
      </ref>
      <ref id="b13-cln63_2p0281">
        <label>13</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hillner</surname>
              <given-names>BE</given-names>
            </name>
            <name>
              <surname>Ingle</surname>
              <given-names>JN</given-names>
            </name>
            <name>
              <surname>Chlebowski</surname>
              <given-names>RT</given-names>
            </name>
            <name>
              <surname>Gralow</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Yee</surname>
              <given-names>GC</given-names>
            </name>
            <name>
              <surname>Janjan</surname>
              <given-names>NA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer</article-title>
          <source>J Clin Oncol</source>
          <year>2003</year>
          <volume>21</volume>
          <fpage>4042</fpage>
          <lpage>57</lpage>
          <pub-id pub-id-type="pmid">12963702</pub-id>
        </citation>
      </ref>
      <ref id="b14-cln63_2p0281">
        <label>14</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Conte</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Guarneri</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Safety of intravenous and oral bisphosphonates and compliance with dosing regimens</article-title>
          <source>Oncologist</source>
          <year>2004</year>
          <volume>9</volume>
          <issue>Suppl 4</issue>
          <fpage>28</fpage>
          <lpage>37</lpage>
          <pub-id pub-id-type="pmid">15459427</pub-id>
        </citation>
      </ref>
      <ref id="b15-cln63_2p0281">
        <label>15</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marx</surname>
              <given-names>RE</given-names>
            </name>
          </person-group>
          <article-title>Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic</article-title>
          <source>J Oral Maxillofac Surg</source>
          <year>2003</year>
          <volume>61</volume>
          <fpage>1115</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">12966493</pub-id>
        </citation>
      </ref>
      <ref id="b16-cln63_2p0281">
        <label>16</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ruggiero</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Mehrotra</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Rosenberg</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Engroff</surname>
              <given-names>SL</given-names>
            </name>
          </person-group>
          <article-title>Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases</article-title>
          <source>J Oral Maxillofac Surg</source>
          <year>2004</year>
          <volume>62</volume>
          <fpage>527</fpage>
          <lpage>34</lpage>
          <pub-id pub-id-type="pmid">15122554</pub-id>
        </citation>
      </ref>
      <ref id="b17-cln63_2p0281">
        <label>17</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Russell</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Bisaz</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Fleisch</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Currey</surname>
              <given-names>HL</given-names>
            </name>
            <name>
              <surname>Rubinstein</surname>
              <given-names>HM</given-names>
            </name>
            <name>
              <surname>Dietz</surname>
              <given-names>AA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Inorganic pyrophosphate in plasma, urine, and synovial fluid of patients with pyrophosphate arthropathy (chondrocalcinosis or pseudogout)</article-title>
          <source>Lancet</source>
          <year>1970</year>
          <volume>2</volume>
          <fpage>899</fpage>
          <lpage>902</lpage>
          <pub-id pub-id-type="pmid">4097282</pub-id>
        </citation>
      </ref>
      <ref id="b18-cln63_2p0281">
        <label>18</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rogers</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Gordon</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Benford</surname>
              <given-names>HL</given-names>
            </name>
            <name>
              <surname>Coxon</surname>
              <given-names>FP</given-names>
            </name>
            <name>
              <surname>Luckman</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Monkkonen</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cellular and molecular mechanisms of action of bisphosphonates</article-title>
          <source>Cancer</source>
          <year>2000</year>
          <volume>88</volume>
          <issue>12 Suppl</issue>
          <fpage>2961</fpage>
          <lpage>78</lpage>
          <pub-id pub-id-type="pmid">10898340</pub-id>
        </citation>
      </ref>
      <ref id="b19-cln63_2p0281">
        <label>19</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hortobagyi</surname>
              <given-names>GN</given-names>
            </name>
            <name>
              <surname>Theriault</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Porter</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Blayney</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Lipton</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sinoff</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group</article-title>
          <source>N Engl J Med</source>
          <year>1996</year>
          <volume>335</volume>
          <fpage>1785</fpage>
          <lpage>91</lpage>
          <pub-id pub-id-type="pmid">8965890</pub-id>
        </citation>
      </ref>
      <ref id="b20-cln63_2p0281">
        <label>20</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Theriault</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Lipton</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hortobagyi</surname>
              <given-names>GN</given-names>
            </name>
            <name>
              <surname>Leff</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Gluck</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Stewart</surname>
              <given-names>JF</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group</article-title>
          <source>J Clin Oncol</source>
          <year>1999</year>
          <volume>17</volume>
          <fpage>846</fpage>
          <lpage>54</lpage>
          <pub-id pub-id-type="pmid">10071275</pub-id>
        </citation>
      </ref>
      <ref id="b21-cln63_2p0281">
        <label>21</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Santini</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Vespasiani Gentilucci</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Vincenzi</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Picardi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Vasaturo</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>La Cesa</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The antineoplastic role of bisphosphonates: from basic research to clinical evidence</article-title>
          <source>Ann Oncol</source>
          <year>2003</year>
          <volume>14</volume>
          <fpage>1468</fpage>
          <lpage>76</lpage>
          <pub-id pub-id-type="pmid">14504045</pub-id>
        </citation>
      </ref>
      <ref id="b22-cln63_2p0281">
        <label>22</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Durie</surname>
              <given-names>BG</given-names>
            </name>
            <name>
              <surname>Katz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Crowley</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Osteonecrosis of the jaw and bisphosphonates</article-title>
          <source>N Engl J Med</source>
          <year>2005</year>
          <volume>353</volume>
          <fpage>99</fpage>
          <lpage>102</lpage>
          <pub-id pub-id-type="pmid">16000365</pub-id>
        </citation>
      </ref>
      <ref id="b23-cln63_2p0281">
        <label>23</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Migliorati</surname>
              <given-names>CA</given-names>
            </name>
          </person-group>
          <article-title>Bisphosphanates and oral cavity avascular bone necrosis</article-title>
          <source>J Clin Oncol</source>
          <year>2003</year>
          <volume>21</volume>
          <fpage>4253</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="pmid">14615459</pub-id>
        </citation>
      </ref>
      <ref id="b24-cln63_2p0281">
        <label>24</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Melo</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Obeid</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy</article-title>
          <source>J Can Dent Assoc</source>
          <year>2005</year>
          <volume>71</volume>
          <fpage>111</fpage>
          <lpage>3</lpage>
          <pub-id pub-id-type="pmid">15691429</pub-id>
        </citation>
      </ref>
      <ref id="b25-cln63_2p0281">
        <label>25</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maerevoet</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Duck</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Osteonecrosis of the jaw and bisphosphonates</article-title>
          <source>N Engl J Med</source>
          <year>2005</year>
          <volume>353</volume>
          <fpage>99</fpage>
          <lpage>102</lpage>
          <pub-id pub-id-type="pmid">16003838</pub-id>
        </citation>
      </ref>
      <ref id="b26-cln63_2p0281">
        <label>26</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Assouline-Dayan</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Greenspan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Shoenfeld</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Gershwin</surname>
              <given-names>ME</given-names>
            </name>
          </person-group>
          <article-title>Pathogenesis and natural history of osteonecrosis</article-title>
          <source>Semin Arthritis Rheum</source>
          <year>2002</year>
          <volume>32</volume>
          <fpage>94</fpage>
          <lpage>124</lpage>
          <pub-id pub-id-type="pmid">12430099</pub-id>
        </citation>
      </ref>
      <ref id="b27-cln63_2p0281">
        <label>27</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carter</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Goss</surname>
              <given-names>AN</given-names>
            </name>
            <name>
              <surname>Doecke</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Bisphosphonates and avascular necrosis of the jaw: a possible association</article-title>
          <source>Med J Aust</source>
          <year>2005</year>
          <volume>182</volume>
          <fpage>413</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="pmid">15850439</pub-id>
        </citation>
      </ref>
      <ref id="b28-cln63_2p0281">
        <label>28</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ficarra</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Beninati</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Rubino</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Vannucchi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Longo</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Tonelli</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment</article-title>
          <source>J Clin Periodontol</source>
          <year>2005</year>
          <volume>32</volume>
          <fpage>1123</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">16212571</pub-id>
        </citation>
      </ref>
      <ref id="b29-cln63_2p0281">
        <label>29</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Katz</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Endodontic implications of bisphosphonate-associated osteonecrosis of the jaws: a report of three cases</article-title>
          <source>J Endod</source>
          <year>2005</year>
          <volume>31</volume>
          <fpage>831</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="pmid">16249730</pub-id>
        </citation>
      </ref>
      <ref id="b30-cln63_2p0281">
        <label>30</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Van den Wyngaert</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Huizing</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Vermorken</surname>
              <given-names>JB</given-names>
            </name>
          </person-group>
          <article-title>Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy?</article-title>
          <source>Ann Oncol</source>
          <year>2006</year>
          <volume>17</volume>
          <fpage>1197</fpage>
          <lpage>204</lpage>
          <pub-id pub-id-type="pmid">16873439</pub-id>
        </citation>
      </ref>
      <ref id="b31-cln63_2p0281">
        <label>31</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Migliorati</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Schubert</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Peterson</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Seneda</surname>
              <given-names>LM</given-names>
            </name>
          </person-group>
          <article-title>Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy</article-title>
          <source>Cancer</source>
          <year>2005</year>
          <volume>104</volume>
          <fpage>83</fpage>
          <lpage>93</lpage>
          <pub-id pub-id-type="pmid">15929121</pub-id>
        </citation>
      </ref>
    </ref-list>
  </back>
  <floats-wrap>
    <fig id="f1-cln63_2p0281" position="float">
      <label>Figure 1</label>
      <caption>
        <p>Ulcered jaw lesion with local purulent secretion due to osteonecrosis after zoledronic acid treatment</p>
      </caption>
      <graphic xlink:href="cln63_2p0281f1"/>
    </fig>
    <fig id="f2-cln63_2p0281" position="float">
      <label>Figure 2</label>
      <caption>
        <p>Panoramic x-ray showing bisphosphonate-induced osteonecrosis in the left jaw</p>
      </caption>
      <graphic xlink:href="cln63_2p0281f2"/>
    </fig>
  </floats-wrap>
</article>
</pmc-articleset>
